Supporting health through culturing the “unculturable”
The human gut microbiome, i.e. all the bacteria that live inside the gut, controls virtually all aspects of human health. Dysregulation of the microbiome has been implicated in many chronic medical conditions including allergies, gastrointestinal disorders, obesity, and cancer. Recent scientific knowledge on the dysregulation of the microbiome in these conditions provides a novel opportunity to develop targeted therapies through microbiome modulation.
Rebalancing the Microbiome
However, targeted microbiome modulation is currently not possible because most bacterial strains in the human gut cannot be cultured and scaled under well known laboratory conditions. MicroInventa solves this critical bottleneck by building a culturomics platform that enables culturing of the ‘unculturable’ bacteria with high throughput. These bacterial strains are subsequently used for the development of diagnostic and drug discovery pipelines.
At the macro scale we use state-of-the-art automated liquid handling and robotics to ensure a high throughput of sample processing. The modularity of our platform enables the streamlining of all procedures for maximum efficiency.
Parallelization is key to delivering our products in a timely manner. To this end we are developing novel micro- and meso-fluidic systems with world-leading specialists to culture and quality-control our bacterial strains.
In addition to our hardware, we take a data-driven approach to optimize bacterial strain discovery and culture. We develop and use powerful algorithms to model bacterial growth rate and growth conditions. This approach complements our hardware in further increasing the throughput we can achieve.
Our proprietary technology platform identifies and cultures bacterial strains, which we provide to our clients for the development of diagnostic and drug discovery purposes. Through our platform we are accelerating the pipeline from product to clinical testing.
Ha Thi Hoang, MD, PhD
Thi is a multi-award winning scientist and medical doctor with a longstanding passion for personalized medicine. He has 8+ years experience in molecular biology, cell biology, biochemistry and clinical medicine. He was research fellow at Yale University and obtained his PhD in Molecular Biology from Cambridge University. He was scholar of the German National Academic Foundation and obtained prestigious scholarships from the Cambridge University Trust and the Boehringer Ingelheim Fonds.
Yunyun Sun, PhD
Yunyun is a chemist and chemical biologist in the field of Drug Discovery and Development. She obtained her PhD in chemistry from the renowned lab of Prof. Edward Tate at Imperial College London, where she developed novel chemical probes using proteomics. She received multiple awards and her
research was supported by the prestigious Imperial College London Rector's Scholarship and E F Kernahan Fund.
AbdulShakur Abdullah, MSc
Shakur has 9+ years of experience working in Next Generation Sequencing and microbiome research as well as 5 years of experience working with culturing techniques ranging from Escherichia coli to Thermoplasma volcanium. He has worked for numerous startups, including GeneDx and CosmosID, where he conducted clinical NGS and oversaw laboratory experimentation to validate advanced sequencing algorithms. Most recently, he was a master's laboratory instructor at Imperial College London.
Ha Thi Hoang
Arthur HillerCEO of Antyllus Therapeutics, Inc.
Arthur has extensive experience across a wide range of functional areas and segments of the life sciences industry. As CEO of Cambridge-based SciFluor Life Sciences, LLC, Arthur led the way for preclinical development of 13 new compounds for use in treating CNS diseases, infectious disease, and inflammation. Arthur has held executive positions at Millennium Pharmaceuticals, Inc. and Merck and Co. Arthur holds a Bachelor’s Degree in journalism from Northwestern University and a Master’s Degree in Business Policy from Columbia University.
Prof. Klaus Drese, PhDCoburg University of Applied Sciences
Klaus is an internationally renowned expert in the field of microfluidics, computational physics and chemical and biochemical analysis systems. He was scientific director at the Fraunhofer ICT-IMM and is currently head of the Institute of Sensor and Actuator Technology at Coburg University of Applied Science. Klaus has published over 100 papers in leading journals of his field and serves as advisor for multiple companies. He obtained his PhD in Physics from the University of Marbug, Germany.